Novozymes A/S

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novonesis A/S engages in the era of biosolutions. It innovate and develop transformative biosolutions that improve the way the world produces, consumes, and lives. The company was founded on January 29, 2024 is headquartered in Lyngby, Denmark.

Novozymes delivered 9% organic sales growth in the first nine months of 2022 and 6% organic sales growth in the third quarter. As announced on October 7, the full-year organic sales growth outlook was raised from 6-8 % to now 8-9 % following a strong performance in the first nine months of the year, and expectedly, continued strong Q4 momentum.

Novozymes confirms upgraded guidance by strong start to Q4

Novozymes Name d EPA Safer Choice Partner of the Year for Second Consecutive Year

Novozymes Named EPA Safer Choice Partner of the Year for Second Consecutive Year

Partners identify new ways to scale Biotalys' first biofungicide more cost-efficiently Partners identify new ways to scale Biotalys' first biofungicide more cost-efficiently

Biotalys and Novozymes announce successful Evoca™ feasibility study

Novozymes A/S (OTCPK:NVZMF) Q2 2022 Earnings Conference Call August 11, 2022 3:00 AM ET Company Participants Tobias Bjorklund - Head of IR Ester Baiget - President and CEO Lars Green - Executive VP and CFO Anders Lund - EVP of Consumer Biosolutions Claus Fuglsang - CSO and Executive VP of Research and Development Amy Byrick - EVP of Strategy and Business Transformation Tina Fanoe - EVP of Agriculture and Industrial Biosolutions Conference Call Participants Alexander Jones - Bank of America Michael Novod - Nordea Georgina Fraser - Goldman Sachs Chetan Udeshi - JPMorgan Sebastian Bray - Berenberg Charles Bentley - Jefferies Charles Eden Sedan - UBS Søren Samsøe - SEB Lars Topholm - Carnegie André Thormann - C&I Operator Welcome to Novozymes Conference Call regarding the First Half 2022 Results. [Operator Instructions] Today, I'm pleased to announce Tobias Bjorklund, Head of Investor Relations.

Novozymes A/S (NVZMF) CEO Ester Baiget on Q2 2022 Results - Earnings Call Transcript

Novozymes delivered solid earnings and double-digit organic sales growth in both the first half and in the second quarter. Despite the volatile market environment, the company narrows its full-year organic sales outlook upwards from 4-8% to now 6-8% and raises EBIT-margin expectations from 25-26% to now 26-27%.

Novozymes delivers strong half year results and narrows full-year outlook upwards

Novozymes has experienced unprecedented cost-inflation on raw materials, energy, and logistics. T o recover these headwinds, substantial price increases will be implemented.

Novozymes plan to further increase prices across the portfolio in response to the significant and persistent hike in incoming cost

Novozymes' financial calendar 2023. Read the full announcement in PDF

Novozymes' financial calendar 2023

Please read the full announcement in the attached PDF

Transactions under Novozymes' stock buyback program

Ghent, BELGIUM and Copenhagen, DENMARK , June 21, 2022 (GLOBE NEWSWIRE) -- Biotalys (Euronext - BTLS), an Agricultural Technology (AgTech) company protecting crops and food with protein-based biocontrol solutions, and N ovozymes, a world leader in biotech solutions, today announced that the companies have entered into a partnership to expand opportunities for Evoca™*, Biotalys' first proprietary biocontrol.

Biotalys and Novozymes Enter into Partnership to Expand Opportunities for Evoca™

Element Solutions Inc

ESI vs. NVZMY: Which Stock Is the Better Value Option?

ESI vs. NVZMY: Which Stock Should Value Investors Buy Now?

Consumer and regulatory demands for more sustainable clothing and textiles are growing and the fashion industry is rising to the challenge. Now Novozymes offers biopolishing for manmade cellulosic fibers (MMCF) including viscose, modal and lyocell. This helps enhance the quality of fabrics, making them look new for longer and extending their lifespan.

Novozymes extends the lifetime of textiles with sustainable innovation

ICL-Israel Chemicals

ICL vs. NVZMY: Which Stock Is the Better Value Option?

Shanghai, China--(Newsfile Corp. - May 30, 2022) - On May 28, the White Paper on Helicobacter Pylori research by OneHealth, an industry leader, was officially released. In recent years, as a human pathogen with nearly half of the global infection rate, the treatment research of Helicobacter Pylori has attracted much attention. OneHealth (the Human Health Department of Novozymes Group) and Follow Your Gut Research Institute jointly released the "White Paper on Pylopass™ Lactobacillus Reuteri DSM...

Industry Leader Novozymes OneHealth's White Paper on Helicobacter Pylori Research was Officially Released

Novozymes A/S (OTCPK:NVZMF) Q1 2022 Results Conference Call April 27, 2022 3:00 AM ET Company Participants Tobias Bjorklund - Head, IR Ester Baiget - CEO Lars Green - CFO Tina Fanoe - EVP, Agriculture & Industrial Biosolutions Amy Byrick - EVP, Strategy & Business Transformation Anders Lund - EVP, Consumer Biosolutions Conference Call Participants Gunther Zechmann - Bernstein Nicola Tang - BNP Paribas Exane Michael Novod - Nordea Charles Bentley - Jefferies Lars Topholm - Carnegie Alex Jones - Bank of America Soren Samsoe - SEB Tobias Bjorklund Thank you very much, operator, and welcome, everyone, to Novozymes' first quarter 2022 conference call. My name is Tobias Bjorklund, and I'm the Head of Investor Relations here at Novozymes.

Novozymes A/S (NVZMF) CEO Ester Baiget on Q1 2022 Results - Earnings Call Transcript

Novozymes delivered solid earnings and double-digit organic sales growth in the first quarter of 2022. Despite negative effects of the tragic war in Ukraine the company increases its full-year organic sales growth from 3-7% to now 4-8%.

Novozymes delivers strong 2022 Q1 results and raises full-year financial guidance

Novozymes has experienced unprecedented inflation on raw materials, energy, and logistics. T o recover these headwinds price increases will be implemented.

Novozymes announces plan to increase prices to cover rising cost of raw materials, energy, and logistics

Resolutions from Novozymes A/S' Annual Shareholders' Meeting 2022

Invitation to Novozymes' annual shareholders' meeting 2022

Novozymes A/S (NVZMF) CEO Ester Baiget on Q4 2021 Results - Earnings Call Transcript

Enzymes maker Novozymes on Tuesday reported fourth quarter operating profit slightly below expectations but said it expected sales to grow organically by between 3-7% in the next financial year.

Novozymes reports Q4 operating profit below estimates

Novozymes is executing on its strategic framework by delivering 6% organic sales growth for 2021 and presenting a solid organic growth outlook of 3-7% for 2022. The company is also on track to meet its ambitious non-financial targets and deliver on its plan to enable a healthier planet.

Novozymes delivers strong 2021 full-year results and expects continued, solid progress in 2022

Celanese

CE vs. NVZMY: Which Stock Is the Better Value Option?

CE vs. NVZMY: Which Stock Should Value Investors Buy Now?

The partnership will develop new biotech solutions aimed at carbon capture through enzymes.

News for Novozymes A/S Stock (NVZMY)